# metastatic non-small cell lung cancer FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/metastatic-non-small-cell-lung-cancer

> 4 upcoming FDA catalysts in metastatic non-small cell lung cancer: Tagrisso® (osimertinib, AZN) on Jan to Apr 2027 (topline data readout); Tagrisso® (osimertinib, AZN) on January 2027 (primary completion); platinum based chemotherapy (NVCR) on October 2028 (primary completion); platinum based chemotherapy (NVCR) on Oct 2028 to Jan 2029 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: half-year only, exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| 2H 2026 | [XTX501 trial start](https://sec-api.dev/pdufa/xtx501) | XLO | metastatic non-small cell lung cancer | scheduled | "Xilio plans to initiate a Phase 1 trial for XTX501 in the second half of 2026 and report initial Phase 1 data in patients with metastatic non-small cell lung cancer in the second half of 2027, subject to clearance of the IND by the U.S. Food and Drug Administration." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1840233/000119312526218194/xlo-ex99_1.htm)) |
| August 17, 2026 | [Volrustomig primary completion](https://sec-api.dev/pdufa/volrustomig) | AZN | Metastatic Non-small Cell Lung Cancer | completed | "NCT05984277 (A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-17 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05984277)) |
| Aug to Nov 2026 | [Volrustomig topline data readout](https://sec-api.dev/pdufa/volrustomig) | AZN | Metastatic Non-small Cell Lung Cancer | scheduled | "NCT05984277 (A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-17 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05984277)) |
| Jan to Apr 2027 | [Tagrisso® (osimertinib) topline data readout](https://sec-api.dev/pdufa/osimertinib) | AZN | Metastatic Non-small Cell Lung Cancer | scheduled | "NCT06417814 (A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-11 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06417814)) |
| January 2027 | [Tagrisso® (osimertinib) primary completion](https://sec-api.dev/pdufa/osimertinib) | AZN | Metastatic Non-small Cell Lung Cancer | scheduled | "NCT06417814 (A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-11 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06417814)) |
| October 2028 | [Platinum based chemotherapy primary completion](https://sec-api.dev/pdufa/platinum-based-chemotherapy) | NVCR | Metastatic Non-small Cell Lung Cancer | scheduled | "NCT06216301 (LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor NovoCure GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06216301)) |
| Oct 2028 to Jan 2029 | [Platinum based chemotherapy topline data readout](https://sec-api.dev/pdufa/platinum-based-chemotherapy) | NVCR | Metastatic Non-small Cell Lung Cancer | scheduled | "NCT06216301 (LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor NovoCure GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06216301)) |

## Drugs

- [XTX501](https://sec-api.dev/pdufa/xtx501) (XLO)
- [Volrustomig](https://sec-api.dev/pdufa/volrustomig) (AZN)
- [Tagrisso® (osimertinib)](https://sec-api.dev/pdufa/osimertinib) (AZN)
- [Platinum based chemotherapy](https://sec-api.dev/pdufa/platinum-based-chemotherapy) (NVCR)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/metastatic-non-small-cell-lung-cancer.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "metastatic non-small cell lung cancer FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/metastatic-non-small-cell-lung-cancer

```bibtex
@misc{secapidev_indications_metastatic_non_small_cell_lung_cancer_20261116,
  title        = {metastatic non-small cell lung cancer FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/metastatic-non-small-cell-lung-cancer}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_metastatic_non_small_cell_lung_cancer_20261116","title":"metastatic non-small cell lung cancer FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/metastatic-non-small-cell-lung-cancer","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
